Írsko - angličtina - HPRA (Health Products Regulatory Authority)

koanaa healthcare limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

aspire pharma limited - bortezomib - powder for solution for injection - 1 milligram(s) - other antineoplastic agents; bortezomib

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

aspire pharma limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - bortezomib - solution for injection - 2.5 milligram(s)/millilitre - other antineoplastic agents; bortezomib

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

medac gesellschaft für klinische spezialpräparate mbh - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: nitrogen; mannitol - bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection), in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection), as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection) is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bortezomib, quantity: 1 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection), in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection), as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection) is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib juno (bortezomib 1 mg and 3.5 mg powder for injection) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Malajzia - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - bortezomib -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bortezomib, quantity: 2.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib juno in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib juno as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib juno is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib juno in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.